Change over period: —
NSE · ONESOURCE
ONESOURCE
-15.1% from the 52-week high · +42.4% above the low
Onesource Specialty Pharma Ltd develops and distributes niche pharmaceutical products, catering to specialized therapeutic areas. The company integrates research, regulatory compliance, and supply chain management for effective healthcare delivery.
The short version. ONESOURCE reported revenue of ₹449 crore for Jun 2026, up 37.3% from a year earlier. Return on equity was -1.3% in Mar 2026. Promoter holding was 30.47% in Sep 2026, down 7.30 points over 8 quarters.
1 · The price
How has the stock traded?
ONESOURCE trades 15.1% below its 52-week high and 42.4% above its 52-week low.
2 · The business
Is it growing?
Jun 2026 revenue of ₹449 cr.
5.7 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 449 | 428 | 290 | 376 | 327 | 426 | 393 | 68 |
| Net profit | 25 | 5 | -89 | 10 | 0 | 98 | -67 | -39 |
| Net margin % | 5.6 | 1.1 | -30.6 | 2.8 | -0.1 | 23.1 | -17.1 | -57.8 |
| EPS (₹) | 2.18 | 0.4 | -7.74 | 0.92 | -0.02 | 8.58 | -5.85 | -3.44 |
Annual
| FY2026 | FY2025 | |
|---|---|---|
| Revenue | 1422 | 1445 |
| Net profit | -74 | -18 |
| Net margin % | -5.2 | -1.2 |
| EPS (₹) | -6.44 | -1.57 |
3 · The quality
How well does it turn capital into profit?
Return on equity was -1.3% in Mar 2026; debt to equity is 0.22.
Profitability · 2 years
Returns and margins
| Mar 2026 | Mar 2025 | |
|---|---|---|
| Return on equity % | -1.3 | -0.3 |
| Return on capital % | 0.4 | 1.5 |
| EBITDA margin % | 21.5 | 25.5 |
| Net margin % | -5.1 | -1.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 7.3 pts over 8 quarters.
Up 2.02 pts over 8 quarters.
Up 11.65 pts over 8 quarters.
+28 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 37.77 | 34.25 | 29.79 | 29.77 | 29.93 | 30.48 | 30.48 | 30.47 | -7.3 |
| FII | 17.44 | 18.54 | 18.69 | 19.39 | 19.24 | 17.5 | 19.19 | 19.46 | +2.02 |
| DII | 12.56 | 18.04 | 18.1 | 18.49 | 18.81 | 20.61 | 23.38 | 24.21 | +11.65 |
| Public | 32.23 | 29.17 | 33.42 | 32.35 | 32.02 | 31.41 | 26.94 | 25.86 | -6.37 |
Mutual fund holdings · Oct 2026
101 schemes hold this stock
73 the month before.
- JM Focused Fund4.3% of NAV
- Motilal Oswal ELSS Tax Saver Fund3.65% of NAV
- Motilal Oswal Large and Midcap Fund3.04% of NAV
- Mirae Asset Healthcare Fund3.04% of NAV
- Motilal Oswal Special Opportunities Fund3.03% of NAV
- Motilal Oswal Flexicap Fund2.92% of NAV
- Motilal Oswal Active Momentum Fund2.59% of NAV
- 360 ONE Focused Fund2.55% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ONESOURCE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ONESOURCE
What is the ONESOURCE share price?
ONESOURCE (ONESOURCE) last closed at ₹1,609.90, up 1.49% on the day. Its 52-week range is ₹1,114.00 to ₹1,867.40.
What is the market cap of ONESOURCE?
ONESOURCE has a market capitalisation of about ₹18,161 crore.
How are ONESOURCE's latest results?
ONESOURCE reported revenue of ₹449 crore for Jun 2026, up 37.3% from a year earlier. Return on equity was -1.3% in Mar 2026. Promoter holding was 30.47% in Sep 2026, down 7.30 points over 8 quarters.
Who owns ONESOURCE?
As of Sep 2026, shareholding was: Promoter 30.47%, FII 19.46%, DII 24.21%, Public 25.86%.
How many mutual funds hold ONESOURCE?
101 mutual fund schemes held ONESOURCE in October 2026. That compares with 73 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.